Industry & Research
Genflow SIRT6 Therapy Meets Endpoint in Aged-Dog Study
Genflow Biosciences Plc (LSE: GENF; OTCQB: GENFF) announced on September 8, 2026, that its SIRT6 gene-therapy study in aged dogs met its primary endpoint. The company said treated animals showed an improvement in biological age compared with untreated controls, as measured using a DNA-methylation clock. The randomized and blinded SLAB study enrolled 24 beagles over…
NurExone Targets H1 2027 IND Filing for ExoPTEN
NurExone Biologic Inc. (TSXV: NRX; OTCQB: NRXBF; FSE: J90) is targeting a potential investigational new drug submission for ExoPTEN during the first half of 2027 as it advances preclinical and manufacturing activities for the experimental therapy. The timeline was included in NurExone’s second-quarter update, released August 31. ExoPTEN is an exosome-based candidate being developed for…
Rhelion Adds U.S. Patent to PEX010 Psilocybin Platform
Rhelion Life Sciences Corp. (CSE: RHEL; OTCQB: TRUFF; FSE: 4YX0) announced on August 27, 2026, that its wholly owned subsidiary Filament Health added a new U.S. patent covering a natural-source psychoactive alkaloid extraction process. U.S. Patent No. 12,697,564, titled “Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids,” was issued on August 4. The patent names Filament subsidiary…
What Is the Role of Patient Advocacy Groups in Drug Development? A Growing Force in Biotech
Behind many of the most significant drug development programs in rare disease and beyond, patient advocacy groups play a role that extends far beyond emotional support and awareness campaigns. These organizations increasingly fund early-stage research, help design clinical trials to better reflect patient priorities, assist with the difficult task of recruiting patients for rare disease…
Stowers Institute’s PISA Decodes AI Models Trained on DNA
Researchers at the Stowers Institute for Medical Research, a nonprofit basic-research institute in Kansas City, published a new method on August 25 for figuring out what an AI model has actually learned when it makes predictions from DNA sequence, rather than just trusting that its predictions are correct. The method, called PISA, is described in…
BriaCell Advances Bria-MEL+ Melanoma Vaccine Toward the Clinic
BriaCell Therapeutics Corp. (TSX: BCT; Nasdaq: BCTX, BCTXL) announced on August 24, 2026, that its Bria-MEL+ personalized melanoma immunotherapy candidate reached a key genetic-engineering milestone. According to the company’s announcement, development activities are underway to support production for potential clinical use. Bria-MEL+ is a genetically modified, whole-cell cancer vaccine designed to activate both innate and…
What Is Peer Review in Biotech Research? Why Publication Matters for Evaluating Clinical Data
When a biotech company issues a press release announcing positive Phase 3 results, that announcement typically precedes — often by months — the full peer-reviewed publication of the underlying data in a scientific journal. This gap between top-line press release data and full peer-reviewed publication is one of the most consequential but least understood aspects…
Defence Therapeutics Names Ryan Simms to Lead Radiopharma Programs
Defence Therapeutics Inc. (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Ryan Simms, PhD, as chief operating officer and head of radiopharmaceutical programs. The Canadian biotechnology company said Simms will oversee the development and operational planning of its radiopharmaceutical drug conjugate pipeline. Simms brings more than 20 years of experience in targeted radiopharmaceutical development. His…
What Is a Contract Research Organization (CRO)? The Companies That Run Clinical Trials
Behind almost every clinical trial reported in a biotech press release is a contract research organization — a specialized company hired to manage some or all of the operational complexity of running the trial. CROs are among the least visible but most structurally important companies in the biotech ecosystem, and understanding what they do, how…
Kane Biotech Engages DNA Advisors to Explore Strategic Alternatives
Kane Biotech Inc. (TSXV: KNE), a Canadian biotechnology company focused on antimicrobial wound care products, has engaged DNA Advisors Inc. as its exclusive financial advisor to evaluate strategic alternatives for the company. According to Kane Biotech’s August 5 announcement, the review may include potential partnerships, financings, acquisitions, commercial collaborations and other strategic transactions. The company…
